Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ONCOLYTICS BIOTECH INC (ONCY)

Oncolytics Biotech shares pelareorep myeloma immune data to be presented at ASH

Neutral Impact 2 of 5 other

Oncolytics Biotech announced translational data from a Phase 1b/2 trial in relapsed/refractory multiple myeloma patients, showing that pelareorep can engage the immune system and combine with standard-of-care therapies. The data will be presented as a poster at the 68th American Society of Hematology Annual Meeting and Exposition, and the filing includes no financial results, guidance, or new trial efficacy figures.

Key points

  • Poster presentation (Abstract 2183) scheduled for Saturday, December 12, 2026 at the ASH Annual Meeting
  • Phase 1b/2 trial compared bortezomib, dexamethasone and pembrolizumab (Cohort 1) with pelareorep plus those drugs (Cohort 2)
  • Patients had a median of four prior lines of therapy, with a range of three to eleven
  • Patients who responded to treatment showed greater expansion of CD8 effector memory T cells than non-responders

The filing

CompanyONCOLYTICS BIOTECH INC (ONCY)
Form8-K, current report
Filed with the SECNov 9, 2026, 9:49 AM ET
Accession number0001129928-26-000080

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:01 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.